Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LH stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Implied fair value · at LH's multiple
Needs LH P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LABCORP HOLDINGS INC. · implied price per share
Bear
$94.57
Base
$113.84
Bull
$148.04
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
LH vs TMO
QUEST DIAGNOSTICS INC
LH vs DGX
WEST PHARMACEUTICAL SERVICES INC
LH vs WST
BAXTER INTERNATIONAL INC
LH vs BAX
MCKESSON CORP
LH vs MCK
AGILENT TECHNOLOGIES, INC.
LH vs A
ILLUMINA, INC.
LH vs ILMN
JOHNSON & JOHNSON
LH vs JNJ
ABBOTT LABORATORIES
LH vs ABT
LOEWS CORP
LH vs L
BERKSHIRE HATHAWAY INC
LH vs BRK-B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LH can narrow its margin gap with DHR while maintaining above-DHR revenue growth, then LH looks attractive at the current price because the stock trades at a clear relative valuation discount; if not, the premium implied by DHR multiple is less compelling given DHR’s superior profitability.
LH trades at a material discount to DHR on most valuation multiples, with P/E at 24.9x versus 36.2x, P/S at 1.5x versus 5.3x, and EV/EBITDA at 12.0x versus 17.5x. The implied price of $378.40 versus the current $260.08 suggests 45.5% upside on DHR P/E framework, but that uplift depends on LH sustaining its current multiple relative to a much higher-quality DHR.
Supporting Metrics
